Phosphodiesterase type IV inhibitors prevent ischemia-reperfusion-induced gastric injury in rats

Journal of Pharmacological Sciences

Volumn 95, Issue 3, 2004, Pages 321-328

  Kyoi, Takashi ^a   Kitazawa, Satoru ^a   Tajima, Koyuki ^a   Zhang, Xin ^a   Ukai, Yojiro ^a  

^a NIPPON SHINYAKU CO LTD   (Japan)

Author keywords

Gastric injury; Irsogladine; Ischemia reperfusion; Phosphodiesterase type IV inhibitor; Rolipram

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; ANTIULCER AGENT; CYTOKINE; IRSOGLADINE MALEATE; MYELOPEROXIDASE; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELIAC ARTERY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; ENZYME INHIBITION; ENZYME SPECIFICITY; ISCHEMIA; MALE; NEUTROPHIL; NONHUMAN; RAT; REOXYGENATION; REPERFUSION INJURY; STOMACH BLOOD FLOW; STOMACH HEMORRHAGE; STOMACH INJURY; STOMACH MUCOSA; STOMACH PROTECTION; ULCER;

EID: 3843056889     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.FPJ04009X     Document Type: Article

References (46)

1. Itoh M, Guth PH. Role of oxygen-derived free radicals in hemorrhagic shock-induced gastric lesions in the rats. Gastroenterology. 1985;88:1162-1168.
2. Perry MA, Wadhwa S, Parks DA, Pickard W, Granger DN. Role of oxygen radicals in ischemia-induced lesions in the cat stomach. Gastroenterology. 1986;90:362-367.
3. Yoshikawa T, Ueda S, Naito Y, Takahashi S, Oyamada H, Morita Y, et al. Role of oxygen-derived free radicals in gastric mucosal injury induced by ischemia or ischemia-reperfusion in rats. Free Rad Res Commun. 1989;7:285-291.
4. Hernandez LA, Grisham MB, Twohig B, Arfors KE, Harlan JM, Granger DN. Role of neutrophils in ischemia-reperfusion-induced microvascular injury. Am J Physiol. 1987;253:H699-H703.
5. Andrews FJ, Malcontenti-Wilson C, O'Brien PE. Polymorphonuclear leukocyte infiltration into gastric mucosa after ischemia-reperfusion. Am J Physiol. 1994;266:G48-G54.
6. Wada K, Kamisaki Y, Kitano M, Nakamoto K, Itoh T. Protective effect of cystathionine on acute gastric mucosal injury induced by ischemia-reperfusion in rats. Eur J Pharmacol. 1995;294:377-382.
7. Engerson TD, McKelvey TG, Rhyne DB, Boggio EB, Snyder SJ, Jones HP. Conversion of xanthine dehydrogenase to oxidase in ischemic rat tissue. J Clin Invest. 1987;79:1564-1570.
8. Kvietys PP, Twohig B, Danzell J, Specian RD. Ethanol-induced injury to the rat gastric mucosa. Gastroenterology. 1990;98:909-920.
9. Teixeira MM, Gristwood RW, Cooper N, Hellewell PG. Phosphodiesterase (PDE4) inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol Sci. 1997;18:164-171.
10. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med. 1998;157: 351-370.
11. Souness JE, Aldous D, Sargent C. Immunosuppressive and anti-inflammatory effects of cAMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology. 2000;47:127-162.
12. Hartmann G, Bidlingmaier C, Siegmund B, Albrich S, Schulze J, Tschoep K, et al. Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J Pharmacol Exp Ther. 2000;292:22-30.
13. Nakamura C, Otaka M, Odashima M, Jin M, Konishi N, Horikawa Y, et al. Rolipram, a specific type IV phosphodiesterase inhibitor, ameliorates indomethacin-induced gastric mucosal injury in rats. Pathophysiology. 2003;9:195-200.
14. Reuter B, Wallace JL. Phosphodiesterase inhibitors prevent NSAID enteropathy independent of effects on TNF-α release. Am J Physiol. 1999;277:G847-G854.
15. Souza DG, Cassali GD, Poole S, Teixeira MM. Effects of inhibition of PDE4 and TNF-α on local and remote injuries following ischemia and reperfusion injury. Br J Pharmacol. 2001;134:985-994.
16. Reeves ML, Leigh BK, England PJ. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors. Biochem J. 1987;241:535-539.
17. Katano Y, Endoh M. Differential effects of Ro 20-1724 and isobutylmethylxanthine on the basal force of contraction and beta-adrenoceptor-mediated response in the rat ventricular myocardium. Biochem Biophys Res Commun. 1990;167:123-129.
18. Ueda F, Aratani S, Mimura K, Kimura K, Nomura A, Enomoto H. Effect of 2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine maleate (MN-1695) on gastric ulcers and gastric secretion in experimental animals. Arzneimittelforschung. 1984;34:474-477.
19. Okabe S, Takeuchi K, Ishihara Y, Kunimi H. Effect of 2,4-diamino-6-(2,5- dichlorophenyl)-s-triazine maleate (MN-1695) on gastric secretion and on experimental gastric ulcers in rats. Pharmacometrics. 1984;24:683-689. (text in Japanese with English abstract)
20. Kyoi T, Oka M, Noda K, Ukai Y. Irsogladine prevents monochloramine- induced gastric mucosal lesions by improving the decrease in mucosal blood flow due to the disturbance of nitric oxide synthesis in rats. J Pharmacol Sci. 2003;93:314-320.
21. Ueda F, Kyoi T, Mimura K, Kimura K, Yamamoto M. Intercellular communication in cultured rabbit gastric epithelial cells. Jpn J Pharmacol. 1991;57:321-328.
22. Iwata F, Joh T, Ueda F, Yokoyama Y, Itoh M. Role of gap junctions in inhibiting ischemia-reperfusion injury of rat gastric mucosa. Am J Physiol. 1998;275:G883-G888.
23. Takahashi N, Joh T, Yokoyama Y, Seno K, Nomura T, Ohara H, et al. Importance of gap junction in gastric mucosal restitution from acid-induced injury. J Lab Clin Med. 2000;136:93-99.
24. Oka M, Noda K, Kyoi T. Suppression of superoxide production in human neutrophils through inhibition of PDE4: an implication for a role of cAMP in anti-ulcer action of irsogladine. J Pharmacol Sci. 2004;94 Suppl 1:251P.
25. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology. 1984;87:1344-1350.
26. Peter K, Hayley JH, Mauro P. Effect of rolipram in a murine model of acute inflammation: comparison with the corticoid dexamethasone. Eur J Pharmacol. 1995;281:69-74.
27. Chitta SK, Carrie LS, Michael PD, Daniel WC. Regulation of IL-15-stimulated TNF-α production by rolipram. J Immunol. 1999;163:2836-2843.
28. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129-135.
29. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, et al. Randomised controlled trial of CDP571 antibody to tumor necrosis factor-α in Crohn's disease. Lancet. 1997;349:521-524.
30. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, Van Hozegaud RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
31. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor-α (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994; 344:1105-1110.
32. Fekade D, Knox K, Hussein K, Melka A, Lallo DG, Coxon RE, et al. Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha. N Engl J Med. 1996;335:311-315.
33. Eigler A, Sinha B, Hartmann G, Endres S. Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today. 1997;18:487-492.
34. Seldon PM, Barnes PJ, Meja K, Giembycz MA. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Mol Pharmacol. 1995;48:747-457.
35. Verghese MW, McConnell RT, Strickland AB, Gooding RC, Stimpson SA, Yarnall DP, et al. Differential regulation of human monocyte-derived TNF-α and IL-1β by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. J Pharmacol Exp Ther. 1995;272:1313-1320.
36. Genain CP, Roberts T, Davis RL, Nguyen MH, Uccelli A, Faulds D, et al. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc Natl Acad Sci USA. 1995;92:3601-3605.
37. Nyman U, Mussener A, Larsson E, Lorentzen J, Klareskog L. Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor Rolipram. Clin Exp Immunol. 1997;108:415-419.
38. Turner CR, Andresen CJ, Smith WB, Watson JW. Effects of rolipram on responses to acute and chronic antigen exposure in monkeys. Am J Respir Crit Care Med. 1994;149:1153-1159.
39. Santucci L, Fiorucci S, Giansanti M, Brunori PM, Di Matteo FM, Morelli A. Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: role of tumour necrosis factor alpha. Gut. 1994;35:909-915.
40. Santucci L, Fiorucci S, Di Matteo FM, Morelli A. Role of tumor necrosis factor α release and leukocyte margination in indomethacin-induced gastric injury in rats. Gastroenterolory. 1995;108:393-401.
41. Kim CD, Hong KW. Preventive effect of rebamipide on gastric lesions induced by ischemia-reperfusion in the rat. J Pharmacol Exp Ther. 1995;275:340-344.
42. Granger DN. Role of xanthine oxidase and granulocytes in ischemia-reperfusion injury. Am J Physiol. 1988;255:H1269-H1275.
43. Puurunen J, Lücke C, Schwabe U. Effect of the phosphodiesterase inhibitor 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711) on gastric secretion and gastric mucosal cyclic AMP. Naunyn Schmiedebergs Arch Pharmacol. 1978;304:69-75.
44. Black EW, Strada SJ, Thompson WJ. Relationships of secretagogue-induced cAMP accumulation and acid secretion in elutriated rat gastric parietal cells. J Pharmacol Meth. 1988; 20:57-78.
45. Wada K, Kamisaki Y, Kitano M, Kishimoto Y, Nakamoto K, Itoh T. A new gastric ulcer model induced by ischemia-reperfusion in the rat: role of leukocytes on ulceration in rat stomach. Life Sci. 1996;59:295-301.
46. Kawai T, Joh T, Iwata F, Itoh M. Gastric epithelial damage induced by local ischemia-reperfusion with or without exogenous acid. Am J Physiol. 1994;266:G263-G270.